Inmed Pharmaceuticals INC 8-K filings

InMed Pharmaceuticals and Mentari Therapeutics announced an amendment to their merger agreement, increasing the pre-closing private placement financing to $200 million.

InMed Pharmaceuticals and Mentari Therapeutics have amended their merger agreement, clarifying transaction sequencing, pre-closing financing impacts, and tax treatment, while also filing a Form S-4 registration statement.

InMed Pharmaceuticals Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a matter previously flagged in March 2026.

InMed Pharmaceuticals Inc. announced a definitive merger agreement with Mentari Therapeutics, Inc., a biotechnology company focused on migraine prevention therapies, aiming to advance Mentari's pipeline with a concurrent $290 million private placement.

InMed Pharmaceuticals Inc. has amended preferred investment options with Armistice Capital Master Fund Ltd., reducing the exercise price from $16.60 to $0.80 per share.

InMed Pharmaceuticals has reduced the exercise price of existing preferred investment options to $0.80 per share for Sabby and H.C. Wainwright affiliates.

InMed Pharmaceuticals Inc. has filed a prospectus supplement related to its At The Market (ATM) offering, detailing the sale of common shares.

InMed Pharmaceuticals announced positive preclinical data for its INM-901 Alzheimer's disease program from human brain organoid neuroinflammation models.

InMed Pharmaceuticals is winding down its BayMedica commercial operations due to impending federal legislation, focusing entirely on its pharmaceutical drug development pipeline.

InMed Pharmaceuticals Inc. shareholders approved the election of five directors, the appointment of CBIZ CPAs P.C. as auditor, and a potential equity issuance plan at its 2025 Annual General and Special Meeting.

InMed Pharmaceuticals announced that new U.S. legislation, H.R. 5371, is expected to have a material negative impact on its BayMedica subsidiary's commercial cannabinoid business.

InMed Pharmaceuticals announced the successful completion of pharmacokinetic studies for its Alzheimer's disease candidate INM-901, demonstrating robust bioavailability and no adverse effects in large animal models.

InMed Pharmaceuticals strengthens its board with the appointment of John Bathery, a seasoned pharmaceutical executive, while Bryan Baldasare steps down.

InMed Pharmaceuticals Inc. announced the dates and details for its 2025 Annual General and Special Meeting of shareholders.

InMed Pharmaceuticals Inc. announced the appointment of Neil Klompas, a seasoned healthcare and biotechnology executive, to its Board of Directors, effective October 9, 2025.

InMed Pharmaceuticals announced its fiscal year 2025 financial results and provided updates on its Alzheimer's and dry AMD drug development programs, alongside BayMedica's revenue growth.

InMed Pharmaceuticals Inc. announced the dates and record information for its 2025 Annual General Meeting of shareholders.

InMed Pharmaceuticals announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where it will present recent data on its lead Alzheimer's program, INM-901.

InMed Pharmaceuticals announced new preclinical data for its INM-901 program, demonstrating multi-modal activity and therapeutic potential in Alzheimer's disease, to be presented at the Alzheimers Association International Conference 2025.

InMed Pharmaceuticals Inc. has successfully closed a $5 million private placement, issuing pre-funded warrants and preferred investment options to a single institutional investor, with proceeds earmarked for drug candidate development, cannabinoid sales, and general working capital.

InMed Pharmaceuticals announced new preclinical data demonstrating that its drug candidate INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, supporting its potential for Alzheimer's disease.

InMed Pharmaceuticals Inc. announced an amendment to its equity purchase agreement, a change in its certifying accountant, and the failure to achieve a quorum at a special shareholder meeting, delaying a critical vote on share issuance.

InMed Pharmaceuticals announced its Q3 fiscal year 2025 financial results, highlighting progress in its Alzheimer's and AMD programs and stable revenue from BayMedica.

InMed Pharmaceuticals Inc. announces the cancellation of the original notice for its special shareholder meeting and provides details for the rescheduled meeting.

InMed Pharmaceuticals has announced a special meeting of securityholders to be held on June 13, 2025.

InMed Pharmaceuticals announces its Q2 fiscal 2025 financial results, highlighting progress in its pharmaceutical pipeline and commercial operations, including positive preclinical data for INM-901 in Alzheimer's disease and the selection of an intravitreal formulation for INM-089 in dry AMD.

InMed Pharmaceuticals announced its second quarter fiscal year 2025 financial results, highlighting progress in its pharmaceutical pipeline and commercial operations.

InMed Pharmaceuticals has announced the selection of an intravitreal formulation for its drug candidate INM-089, targeting the treatment of dry age-related macular degeneration (AMD).

InMed Pharmaceuticals has been granted a key international patent in Mexico for its novel cannabinoid analogs, marking a significant step in protecting its intellectual property.

InMed Pharmaceuticals reports positive preclinical results for INM-901, showing a significant reduction in neuroinflammation markers associated with Alzheimer's disease.